Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

---

Dimopoulos M., Terpos E., Boccadoro M., Delimpasi S., BEKSAÇ M., Katodritou E., ...More

64th ASH Annual Meeting & Exposition, United States Of America, 9 - 12 December 2022, (Full Text)

• Publication Type: Conference Paper / Full Text
• Country: United States Of America
• Ankara University Affiliated: Yes